At Johnson & Johnson Innovative Medicine (J&J) UK, our focus is on Pulmonary Arterial Hypertension (PAH) — a specific, rare form of pulmonary hypertension (PH). ¹

We are spearheading a new era for those living with PAH to transform the disease into a long-term manageable condition, so that patients can live fulfilling lives.

There are five groups of PH, a condition that leads to high blood pressure in the blood vessels. ¹

In the UK, approximately 55 people per million—nearly 4,000 individuals—are affected by PAH. ^{1, 2}

The risk of developing PAH increases with age and is particularly relevant for those living with conditions such as Scleroderma, Congenital Heart Disease, or other Connective Tissue Disorders (CTD). ¹ Our focus is therefore on supporting people in these groups with diagnosis and managing the condition.

With PAH, symptoms might not appear until the condition is advanced, meaning the condition can be difficult to diagnose. ¹

We are committed to transforming the lives of people affected by PAH through innovation and collaboration.

At J&J, our vision in PAH is centered on reducing diagnosis time by supporting education and screening to accelerate referrals to specialists. We are committed to improving the health and quality of life of those affected by PAH, including patients, carers, and families. Through partnerships with the NHS, we aim to empower healthcare professionals and enhance PAH management across the UK healthcare system, while maximising the clinical benefits of our treatments for better patient outcomes. We are driving research and innovation to discover new ways to tackle PAH, and together with patients, healthcare professionals, and advocates, we are making meaningful progress to improve lives and advance PAH care.

Our pioneering medicines and deep understanding of the complex pathways and molecular mechanisms associated with PAH have contributed to improving patient outcomes for PAH communities.

In June 2017, Actelion Pharmaceuticals Ltd became part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Supported by Actelion’s 20-year heritage of pioneering innovation in PAH, we are working to reach more patients and aim to help tackle the diagnosis gap that can delay access to the care that patients need.

We bring to the field of PAH a remarkable track record in scientific discovery and a deep patient-centric focus.

We are committed to partnering with those whose innovative thinking will bring new and creative solutions to the field of medicine